GlaxoSmithKline plc (NYSE:GSK) was upgraded by equities researchers at Berenberg Bank from a “hold” rating to a “buy” rating in a report issued on Friday.

Other equities research analysts also recently issued research reports about the stock. BNP Paribas upgraded shares of GlaxoSmithKline plc from an “underperform” rating to a “neutral” rating and reduced their price target for the company from $45.58 to $37.20 in a research report on Wednesday, April 5th. Exane BNP Paribas upgraded shares of GlaxoSmithKline plc from an “underperform” rating to a “neutral” rating in a research report on Wednesday, April 5th. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline plc in a research report on Tuesday, February 7th. Zacks Investment Research upgraded shares of GlaxoSmithKline plc from a “sell” rating to a “hold” rating in a research note on Tuesday, April 25th. Finally, TheStreet upgraded shares of GlaxoSmithKline plc from a “c” rating to a “b” rating in a research note on Friday, May 19th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $45.25.

Analyst Recommendations for GlaxoSmithKline plc (NYSE:GSK)

GlaxoSmithKline plc (NYSE:GSK) traded up 0.284% during mid-day trading on Friday, reaching $42.691. 4,711,924 shares of the company’s stock traded hands. The company has a 50-day moving average of $41.93 and a 200-day moving average of $40.34. The company has a market capitalization of $104.29 billion, a price-to-earnings ratio of 48.734 and a beta of 0.94. GlaxoSmithKline plc has a 52-week low of $37.20 and a 52-week high of $45.58.

GlaxoSmithKline plc (NYSE:GSK) last issued its quarterly earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.62. The business had revenue of $9.23 billion during the quarter, compared to the consensus estimate of $9.09 billion. GlaxoSmithKline plc had a net margin of 3.11% and a return on equity of 100.68%. Equities research analysts expect that GlaxoSmithKline plc will post $2.83 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 13th. Stockholders of record on Friday, May 12th will be paid a dividend of $0.483 per share. This is a positive change from GlaxoSmithKline plc’s previous quarterly dividend of $0.46. The ex-dividend date is Wednesday, May 10th. This represents a $1.93 annualized dividend and a dividend yield of 4.54%. GlaxoSmithKline plc’s dividend payout ratio is 389.36%.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline plc (GSK) Rating Increased to Buy at Berenberg Bank” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/05/26/glaxosmithkline-plc-gsk-rating-increased-to-buy-at-berenberg-bank.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC raised its position in shares of GlaxoSmithKline plc by 11.7% in the first quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock valued at $996,452,000 after buying an additional 2,482,009 shares during the period. Fisher Asset Management LLC raised its position in shares of GlaxoSmithKline plc by 1.4% in the first quarter. Fisher Asset Management LLC now owns 11,969,866 shares of the pharmaceutical company’s stock valued at $504,650,000 after buying an additional 160,366 shares during the period. State Street Corp raised its position in shares of GlaxoSmithKline plc by 1.7% in the fourth quarter. State Street Corp now owns 10,600,829 shares of the pharmaceutical company’s stock valued at $408,238,000 after buying an additional 180,568 shares during the period. Bank of America Corp DE raised its position in shares of GlaxoSmithKline plc by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock valued at $288,780,000 after buying an additional 934,928 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of GlaxoSmithKline plc by 42.7% in the first quarter. Renaissance Technologies LLC now owns 4,402,100 shares of the pharmaceutical company’s stock valued at $185,593,000 after buying an additional 1,316,600 shares during the period. Institutional investors own 8.41% of the company’s stock.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

12 Month Chart for NYSE:GSK

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.